The intricate role of N6-methyladenosine (m6A), the most abundant internal modification on eukaryotic messenger RNA, has emerged as a crucial epigenetic regulator influencing tumorigenesis and cancer progression. m6A methylation modulates RNA stability, translation, and splicing, thereby orchestrating cellular processes fundamental to malignancy. STM2457, a selective inhibitor of the m6A methyltransferase METTL3, disrupts this pathway, representing an exciting therapeutic candidate for m6A-mediated cancers. However, the intrinsic limitations of monotherapy, including incomplete response and resistance, have necessitated exploring combinatorial strategies to amplify anti-tumor impact.

Astragalus polysaccharide, derived from the traditional Chinese medicinal herb Astragalus membranaceus, has been historically celebrated for its immunomodulatory and anti-inflammatory properties. Modern investigations have unveiled its antineoplastic potential, attributed to mechanisms such as macrophage activation, apoptosis induction, and inhibition of tumor angiogenesis. Wang’s study compellingly elucidates how APS can synergize with STM2457, enhancing its therapeutic efficacy in OSCC through multifaceted molecular pathways.

At the molecular interface, APS appears to facilitate a heightened response to STM2457 by modulating the tumor microenvironment and influencing key signaling cascades integral to OSCC survival and proliferation. Notably, APS treatment was shown to downregulate oncogenic pathways typically reinforced by aberrant m6A methylation, thus complementing STM2457’s mode of action. This dual modulation results in a pronounced suppression of tumor growth and metastasis, exceeding the effects observed with STM2457 monotherapy.

Delving deeper, the study employed rigorous in vitro and in vivo models to dissect the mechanistic basis of APS-driven potentiation. Cellular assays revealed that APS not only augmented the inhibition of METTL3 activity induced by STM2457 but also stabilized the expression of tumor suppressor RNAs usually destabilized through m6A modification. Furthermore, APS was observed to reprogram immune effector cells within the tumor milieu, thereby enhancing antitumor immunity and promoting apoptosis.

Importantly, the epitranscriptomic landscape within OSCC cells was profoundly altered by the combinatorial treatment. High-throughput sequencing demonstrated that the global m6A methylation profile experienced marked shifts, with critical oncogenic transcripts undergoing demethylation and subsequent degradation. This reconfiguration underscores the therapeutic potential of targeting RNA modifications to disrupt cancer-specific gene expression patterns, an area hitherto underexploited.

The implications of this study extend beyond OSCC, as m6A modifications are increasingly recognized in various malignancies, positioning APS and STM2457 as a template for integrated epigenetic interventions. By harnessing a natural product like APS to augment the efficacy of synthetic inhibitors, this research opens avenues for safer, more effective cancer therapeutics that capitalize on synergistic mechanisms instead of relying on higher drug dosages, which often bring toxic side effects.

Moreover, the findings prompt a reconsideration of traditional medicine’s role in modern oncology, highlighting how ancient compounds can be scientifically repurposed within cutting-edge molecular frameworks. APS represents a prototype for bioactive compounds that can modulate the tumor microenvironment and epigenetic regulation, potentially improving patient outcomes when combined judiciously with current targeted agents.

Clinical translation remains a critical frontier. The results mandate well-designed trials to validate the safety and efficacy of APS and STM2457 co-administration in human subjects, optimizing dosage regimens and analyzing potential biomarkers predictive of response. Pharmacokinetic and pharmacodynamic interactions must be characterized to ensure maximal therapeutic synergy with minimal adverse events.

In conclusion, Wang’s investigation into the mechanisms by which APS enhances STM2457 therapeutic outcomes delineates a novel, intricately layered approach to combating m6A-mediated oral cancer. As the oncology community grapples with the challenges of treatment resistance and tumor heterogeneity, such integrative strategies marrying traditional compounds with innovative molecular inhibitors could revolutionize cancer therapy paradigms.

This pioneering work not only deepens our understanding of m6A methylation’s role in OSCC pathogenesis but also underscores the untapped potential residing in natural polysaccharides as adjuncts to precision medicine. The intersection of epitranscriptomics and phytochemistry exemplified in this research marks a promising horizon for the development of next-generation cancer therapeutics with the potential for broad application and improved patient survival.

Subject of Research: The therapeutic mechanisms and efficacy enhancement of astragalus polysaccharide combined with STM2457 in targeting m6A RNA methylation pathways in oral squamous cell carcinoma.

Article Title: Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment.

Article References:
Wang, X. Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment. Med Oncol 43, 122 (2026). https://doi.org/10.1007/s12032-026-03254-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-026-03254-1

Colorectal cancer remains a leading cause of cancer-related mortality worldwide, primarily due to the recurrent failure of chemotherapy. The persistence of cancer stem cells (CSCs) within tumors is widely implicated as a culprit in chemoresistance and disease relapse. These CSCs possess self-renewal properties, allowing them to withstand cytotoxic insults and regenerate malignant growths even after aggressive chemotherapy. However, targeting these cells has been complicated by limited knowledge of the molecular mechanisms regulating their stemness and survival pathways.

At the heart of this investigation lies ALKBH5, an RNA demethylase enzyme known to reverse N6-methyladenosine (m^6A) modifications on mRNA transcripts. The m^6A mark is a widespread epitranscriptomic modification that dynamically tunes RNA stability, splicing, export, and translation. While the addition of m^6A marks has been extensively studied, less is understood about the functional consequences of their removal by erasers like ALKBH5 in the context of cancer biology.

The team employed state-of-the-art transcriptomic profiling and epitranscriptomic mapping to delineate the influence of ALKBH5 on colorectal cancer cells. They discovered that ALKBH5 expression is significantly upregulated in CRC stem cell populations, enabling the erasure of critical m^6A marks that stabilize oncogenic transcripts governing stemness. By demethylating these RNAs, ALKBH5 enhances their stability and translation, thereby sustaining the robust self-renewal capacities and drug resistance mechanisms of CSCs.

Functional validations were conducted using CRISPR-Cas9 mediated gene editing, which demonstrated that knocking out ALKBH5 severely impaired the formation and maintenance of colorectal CSCs. This depletion diminished their ability to form spheroids in vitro, a hallmark of stemness, and sensitized these cells to common chemotherapeutic agents such as 5-fluorouracil and oxaliplatin. Such observations underscore ALKBH5 as a linchpin in the molecular circuitry fostering tumor persistence under chemotherapeutic stress.

Delving deeper, the researchers identified key downstream mRNA targets modulated by ALKBH5-mediated m^6A demethylation. Transcripts encoding regulators of cell cycle progression, DNA repair, and anti-apoptotic pathways were found to be stabilized upon ALKBH5 activity, cumulatively enhancing CSC fitness and survival. Intriguingly, the abrogation of ALKBH5 disrupted these oncogenic transcriptome programs, highlighting its potential as a therapeutic target that strikes at the root of colorectal cancer recurrence.

The implications of this research are profound. Unlike previous therapeutic strategies focused largely on surface markers or signaling pathways, targeting the epitranscriptomic landscape opens a novel and promising avenue for combating tough-to-treat cancers. By pharmacologically inhibiting ALKBH5, it may be possible to simultaneously blunt CSC-driven tumor progression and resensitize tumors to chemotherapy, overcoming one of oncology’s most intractable challenges.

Moreover, the study underscores the complexity and adaptability of cancer cells that exploit epigenetic and epitranscriptomic mechanisms to survive therapy. ALKBH5’s role in the dynamic RNA methylation landscape reveals a previously underappreciated layer of regulation that cancer cells hijack. This not only advances our fundamental understanding of tumor biology but also predicates future research to explore epitranscriptomic modulators across different cancer types.

Importantly, this research paves the way for developing ALKBH5 inhibitors as adjunct therapeutic agents. Given the specificity of ALKBH5 in erasing m^6A marks, targeting this enzyme holds the promise of minimal off-target effects compared to traditional chemotherapy. Early-stage compounds identified through high-throughput screens have demonstrated feasibility, though extensive preclinical and clinical validations are necessary.

The translational potential of targeting ALKBH5 is further bolstered by the identification of biomarkers that predict patient response to ALKBH5-targeted therapies. Elevated ALKBH5 expression correlates with poor prognosis and high CSC burden in colorectal cancer patients, suggesting that stratifying patients based on ALKBH5 levels could optimize therapeutic outcomes.

On a broader scale, this study catalyzes a paradigm shift in precision oncology, emphasizing the importance of the RNA modification landscape alongside genetic and proteomic targets. The interplay between m^6A methylation and cancer pathogenicity beckons a new class of epitranscriptomic therapies that might complement existing immunotherapies and chemotherapies, potentially yielding synergistic effects.

Future directions inspired by this work include the exploration of ALKBH5’s interactions with other m^6A regulators such as METTL3 and FTO, as well as its influence on the tumor microenvironment. Investigating how ALKBH5 modulation affects immune cell infiltration, angiogenesis, and metastatic dissemination will be crucial to fully harness its therapeutic potential.

In conclusion, the targeting of the m^6A RNA demethylase ALKBH5 emerges as an innovative and effective means to undermine colorectal cancer stemness and chemoresistance. By disrupting the epitranscriptomic sustainment of CSCs, this approach offers hope for improved treatment responses and durable remission in a disease that has defied many prior interventions. The study by Zhou, Chen, Liu, and their team marks a significant leap forward in cancer research, heralding a new epoch where RNA methylation dynamics become viable targets in the fight against cancer.

Subject of Research: Targeting the m^6A eraser ALKBH5 to suppress colorectal cancer stemness and chemoresistance.

Article Title: Targeting of the m^6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer.

Article References: Zhou, H., Chen, H., Liu, W. et al. Targeting of the m^6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67502-0

Image Credits: AI Generated